invasive candidiasis – Page 2

Metabolic Patterns of Fluconazole Resistant and Susceptible Candida auris Clade V and I

mycolabadmin

Researchers used advanced chemical analysis to identify different compounds produced by a dangerous fungus called Candida auris that can cause serious infections. They compared fungal strains that were resistant to the antifungal drug fluconazole with those that were susceptible, finding that resistant strains produced different metabolites (chemical compounds) than susceptible ones. These findings could help doctors develop better treatments by identifying what makes this fungus resistant to current medications.

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

Researchers in Iran studied 136 hospital patients to identify different types of Candida fungal infections using a molecular laboratory technique called PCR-RFLP. They found that while Candida albicans remained the most common species, other Candida species were increasingly prevalent in hospitalized patients. The study developed a cost-effective diagnostic method that could help developing countries identify these fungal infections faster and more accurately, though the dangerous multidrug-resistant Candida auris was not found in their samples.

Antifungal Policy and Practice Across Five Countries: A Qualitative Review

mycolabadmin

This study examined how five countries (Netherlands, Italy, South Korea, China, and India) manage invasive fungal infections through national policies. Researchers found that while all countries have some policies in place, there are significant gaps in diagnosis access, treatment availability, and healthcare professional training. The findings highlight the urgent need for stronger, more comprehensive policies to help patients suffering from serious fungal infections.

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal medication called rezafungin to treat a serious eye infection caused by the fungus Candida albicans. Using rabbit models, they found that rezafungin was much more effective than two other antifungal drugs at clearing the infection from the eye and preventing damage to vision. The drug’s ability to work for longer periods with less frequent dosing makes it a promising candidate for treating this devastating infection in patients.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

This study evaluated a simple molecular test called PCR-RFLP to identify different types of Candida fungi in hospitalized patients in Iran. Among 136 patient samples, researchers found eight different Candida species, with common Candida albicans being most prevalent, but other more dangerous species also present. No cases of the emerging pathogen Candida auris were found, though the test method can effectively detect it. The researchers conclude this cost-effective test could be valuable for identifying dangerous fungal infections in developing countries.

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

Diagnostic Capacity for Fungal Infections in Tertiary Hospitals in Nigeria and Ghana – An Onsite Baseline Audit of 9 Sites

mycolabadmin

Researchers audited laboratory facilities in 9 major hospitals (8 in Nigeria, 1 in Ghana) to see how well they could test for fungal infections. They found that most hospitals lacked basic equipment, trained staff, and proper procedures for fungal testing. This is a serious problem because fungal infections can be deadly if not caught early and treated quickly.

Synthesis, Physicochemical Properties and Anti-Fungal Activities of New Meso-Arylporphyrins

mycolabadmin

Researchers created three new porphyrin compounds that effectively kill fungal infections like Candida and athlete’s foot fungi. These compounds can also generate singlet oxygen when exposed to light, making them potentially useful for photodynamic therapy treatments. Testing showed they inhibited fungal growth at relatively low concentrations, suggesting they could become new antifungal medications.

Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance in Candida glabrata

mycolabadmin

Candida glabrata is a dangerous fungus causing serious infections that is becoming resistant to antifungal drugs. Researchers used a genetic screening technique to find genes that interact with drug resistance mutations and identified methotrexate (a drug already used for arthritis) as a potential partner for fluconazole treatment. When combined, these drugs work better together against resistant strains of the fungus, offering hope for treating these stubborn infections.

Disease: invasive candidiasis